Regulatory

Biosergen successfully completes second cohort of BSG005 phase I trial

Release

Regulatory

Announcement from the annual general meeting held on June 28, 2022 in Biosergen AB

Release

Regulatory

Biosergen publishes 2021 Annual report

Release

Regulatory

Biosergen publishes interim report for first quarter 2022

Release
2022-Q1 Financial Report

Regulatory

Biosergen successfully completes first cohort of BSG005 phase I trial

Release

Regulatory

The first subject has been dosed in the phase I trial of BSG005

Release

Regulatory

Biosergen publishes interim report for fourth quarter 2021

Biosergen Q4 financial report press release
Q4-2021 Financial Report

Regulatory

Biosergen publishes interim report for the third quarter 2021

Q3-2021 Financial Report
Biosergen Q3 financial report press release

Regulatory

Biosergen publishes interim report for the second quarter 2021

Q2-2021 Financial Report
Biosergen Q2 report press release

Regulatory

Biosergen’s groundbreaking antifugal drug BSG005 is granted Orphan Drug status in the United States

Release

Regulatory

BIOSERGEN’S OFFERING IS FULLY SUBSCRIBED

Biosergens offering fully subscribed